Tags : Alnylam

PharmaShots Weekly Snapshot (Sept 28 – Oct 1, 2020)

Sobi & Selecta Report Results of SEL-212 in P-II COMPARE Study for Chronic Refractory Gout Published: Oct 1, 2020 | Tags: Chronic Refractory Gout, COMPARE Study, Important Clinical Improvement, P-II, patients, reports, results, SEL-212, Selecta Biosciences, Sobi 2. Moderna’s mRNA-1273 COVID-19 Vaccine Demonstrate Immune Responses in Older Adults Published: Oct 1, 2020 | Tags: COVID-19, […]Read More

Alnylam Reports Results of Lumasiran in P-III ILLUMINATE-B Study for

Shots: The P-III ILLUMINATE-B study involves assessing Lumasiran in 18 patients with PH1 under the age of 6 (3-72mos.), with an eGFR >45 mL/min/1.73 m2 or normal serum creatinine if less than 12mos. old at 9 study sites in 5 countries across the globe The study demonstrated a reduction in the hepatic production of oxalate across all […]Read More

Insights+: COVID-19 Healthcare News Monthly Updates

Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it. The COVID-19 virus has been named “SARS-CoV-2” (severe acute respiratory syndrome coronavirus 2) and the disease it causes has been named “Coronavirus Disease 2019” (COVID-19). The outbreak of the respiratory disease was first detected […]Read More

PharmaShots Weekly Snapshot (April 13 -17, 2020)

1. Sinovac Initiates the P-I Clinical Study for Vaccine Candidate Against COVID-19 Published: Apr 17, 2020 | Tags: Sinovac, Initiates, P-I, Clinical Study, Vaccine Candidate, Against, COVID-19 2. 1Health.io Launches Self-Collection Kits to Detect COVID-19 Published: Apr 16, 2020 | Tags: 1Health.io, Launches, Self-Collection Kits, Detect, COVID-19 3. Chi-Med’s Surufatinib Receives the US FDA’s Fast Track Designations […]Read More

Insights+ COVID-19 Deals (Part I): Biopharma Drug Development

The recent emergence of the coronavirus SARS-CoV-2 and the COVID-19 pandemic has spurred global healthcare and life sciences companies, as well as government agencies, to partner at an unprecedented speed to develop vaccines, treatments, and tests.  This article covers last four months of deal data provided by Chris Dokomajilar of DealForma. During the last four months […]Read More

Alnylam’s Vutrisiran Receives the US FDA’s Fast Track Designation to

Shots: The US FDA has granted FT designation vutrisiran for treating polyneuropathy of hATTR amyloidosis in adults. The designation allows Alnylam to submit NDA for vutrisiran The P-I study assessing Vutrisiran (quarterly dosing with low-volume, SC) demonstrated a reduction in the burden of care for the disease. The safety & efficacy of the therapy are […]Read More

Blackstone and Alnylam Enter into a Collaboration to Accelerate the

Shots: Blackstone to invest $2B in Alnylam that includes $1B in committed payments in exchange of 50% royalties and commercial milestones for inclisiran, ~$750M in a first lien senior secured term loan led by GSO, ~$150M for Alnylam’s cardiometabolic programs (vutrisiran and ALN-AGT) and ~$100M on purchase of Alnylam’s common stock The transaction marks the […]Read More

PharmaShots Weekly Snapshot (April 06 -10, 2020)

Amgen Signs a Partnership with Adaptive Biotechnologies to Develop for COVID-19 Published: Apr 09, 2020 | Tags: Amgen, Adaptive Biotechnologies, Develop, Abs, COVID-19 2.  Samsung Biologics Signs an Agreement with Vir Biotechnology to Develop Abs for COVID-19 Published: Apr 09, 2020 | Tags: Samsung Biologics, Agreement, Vir Biotechnology, Abs, COVID-19 3.  Abbott’s TriClip Transcatheter Tricuspid […]Read More

Alnylam and Dicerna Collaborate to Develop and Commercialize RNAi Therapeutics

Shots: The collaboration will explore Alnylam’s ALN-AAT02 and Dicerna’s DCR-A1AT, each in P-I/II development for the treatment of alpha-1 liver disease. Dicerna will lead the global clinical development and commercialization (US only) of its DCR-A1AT and Alnylam’s ALN-AAT02 Post P-III completion, Alnylam retains an option to commercialize the selected candidate outside the US. If Alnylam […]Read More